Bayer takes another swipe at Nexavar compulsory licence
15-10-2013
A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Nexavar, Bayer, Mumbai High Court, India, Compulsory Licence,
